Johnson & Johnson’s first quarter revenue missed Wall Street estimates on Tuesday with sales of its blockbuster psoriasis drug Stelara coming in lower than expected as the company prepares for its loss of exclusivity in the United States.
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged patent infringement related to their COVID-19 vaccine Comirnaty.
Yesterday Ultragenyx Pharmaceutical provided a Phase I/II update for its investigational antisense oligonucleotide GTX-102, demonstrating substantial symptomatic improvement in patients with the rare genetic disorder Angelman syndrome.
A settlement between Eli Lilly and purchasers of its insulin drugs that would have capped prices and provided $13.5 million to resolve claims that the company inflated the drugs’ cost has fallen apart, after an unfavorable ruling from the judge overseeing the case.
Roche said Monday that its bispecific T-cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.
The batch recalled was made by J&J in South Africa in May 2021 but Kenvue now owns the Benylin Paediatric syrup brand after a spin-off from J&J last year.
AbbVie released interim Phase III data for its calcitonin gene-related peptide receptor blocker Qulipta (atogepant), which demonstrated long-term safety and efficacy for patients in preventing chronic and episodic migraine.
An FDA advisory committee agreed that using minimal residual disease could be a viable surrogate endpoint for accelerated approval for drug development in multiple myeloma.
The agreement had two main components: allogeneic T-cell therapies for up to five cancer targets and personalized allogeneic T-cell-based programs. Both were still in the discovery phase at the time of the termination.
